Mesenchymal Cell News Volume 3.05 | Feb 8 2011

    0
    23

    Mesenchymal Cell News 3.05, February 8, 2011.

         In this issue: Science News | Current Publications | Industry News | Policy News | Events

    TOP STORY
    A Stem Cell-Based Approach to Cartilage Repair
    This work provides new insights into the control of chondrogenesis that may ultimately lead to a stem cell-based therapy for osteoarthritis. [Science] Abstract

    [Free Webinar] ALDH+ Cancer Precursor Cells in Drug Response Prediction - Register Now.

    SPECIAL FEATURE

    social_default_facebook_icon.jpg Cell Therapy News is now on Facebook! Join us.

    social_default_twitter_icon.jpg Follow us on Twitter! @MesenchymalCell

    Interested in recruiting talented individuals? Post your career opportunities in Mesenchymal Cell News at no cost. Contact us at info@connexoncreative.com

    SCIENCE NEWS

    Halozyme’s Ultrafast Insulin Formulations Improved Postprandial Glycemic Control in Patients Living with Type 1 Diabetes: Phase II Study Results
    Data from the Phase II study indicated that the Company’s recombinant human hyaluronidase enzyme reduced postprandial glycemic excursions, as well as significantly reduced hypoglycemic events. [Press release from Halozyme Therapeutics, Inc. discussing research presented at the American Diabetes Association’s 72nd Scientific Sessions, Philadelphia] Press Release

    Interim Data From Pre-administration of Hylenex in Analog Insulin Pump Therapy Demonstrate Consistent Insulin Action Profile
    Halozyme Therapeutics, Inc. presented results from a Phase IV study of Hylenex® recombinant (hyaluronidase human injection) in sensor augmented insulin analog pump (SAP) therapy in patients living with Type 1 diabetes. [Press release from Halozyme Therapeutics, Inc. discussing research presented at the American Diabetes Association’s 72nd Scientific Sessions, Philadelphia] Press Release

    Stem Cell Society Singapore (SCSS) 2012 Symposium: Stem Cell Based Therapy

    CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal)

    Cellular and Extracellular Programming of Cell Fate through Engineered Intracrine-, Paracrine-, and Endocrine-like Mechanisms
    Specifically, researchers show that human mesenchymal stem cells can be engineered with poly lactide-co-glycolic acid particles containing dexamethasone, which acts on cytoplasmic receptors. The controlled release properties of these particles allowed for sustained intracellular and extracellular delivery of agent to promote differentiation of particle-carrying cells, as well as neighboring cells and distant cells that do not contain particles. [Biomaterials]

    In Vivo Magnetic Resonance Imaging of Cell Tropsim, Trafficking Mechanism, and Therapeutic Impact of Human Mesenchymal Stem Cells in a Murine Glioma Model
    In this study, researchers describe the use of ferucarbotran and protamine (Fer-Pro) complexes for labeling human mesenchymal stem cells for MRI tracking of glioma tropism in vivo. [Biomaterials]

    The Effect of Two and Three Dimensional Cell Culture on the Chondrogenic Potential of Human Adipose-Derived Mesenchymal Stem Cells After Subcutaneous Transplantation with an Injectable Hydrogel
    This study aims at investigating the influence of in vitro chondrogenic differentiation of human adipose tissue-derived stem cells on in vivo cartilage formation when associated with a cellulose-based self-setting hydrogel. [Cell Transplant]

    Effect of Dimethyl Sulfoxide (DMSO) on Cryopreservation of Porcine Mesenchymal Stem Cells (pMSCs)
    Researchers compared the viability, colony forming unit-fibroblast (CFU-F) assay, expression of Bak and Bcl2 genes, Bcl2 protein antigen and CD90 in pMSCs cryopreserved with 5, 10 and 20% DMSO. [Cell Transplant]

    Autologous Lung-Derived Mesenchymal Stem Cell Transplantation in Experimental Emphysema
    Autologous lung-derived mesenchymal stem cells (LMSCs) were transplanted endoscopically into sheep with experimental emphysema to assess their capacity to regenerate functional tissue. [Cell Transplant]

    Chondrogenesis from Human Placenta-Derived Mesenchymal Stem Cells (hPMSCs) in 3D Scaffolds for Cartilage Tissue Engineering
    In this study, hPMSCs were grown in a three-dimensional (3D) environment for cartilage tissue formation in vitro. To select proper scaffolds for 3D culture of mesenchymal stem cells (MSCs), rat adipose-derived mesenchymal stem cells (rMSCs) were initially employed to optimize the composition and condition of the 3D environment. [Tissue Eng Part A]

    Microvascular Mural Cell Functionality of Human Embryonic Stem Cell Derived Mesenchymal Cells
    Researchers have developed lines of multipotent mesenchymal cells from human embryonic stem cells (hES-MC) which they hypothesize can function as perivascular mural cells. [Tissue Eng Part A]

    Acute Hepatic Failure-Derived Bone Marrow Mesenchymal Stem Cells Express Hepatic Progenitor Cell Genes
    This study aimed to determine whether bone marrow mesenchymal stem cells isolated from rats in acute hepatic failure (AHF) possess hepatic potential and/or characteristics. [Cells Tissues Organs]

    Schwann-like Mesenchymal Stem Cells Within Vein Graft Facilitate Facial Nerve Reegeneration and Remyelination
    The purpose of this study was to compare the ability of bone marrow mesenchymal stem cells (MSCs) and transdifferentiated Schwann-like MSCs in promoting transected facial nerve branches repair in a rabbit model of injury. [Brain Res]

    MMTC_STM_645x110.jpg

    INDUSTRY NEWS

    BrainStorm Announces Private Equity Financing of $250,000 With Single Institutional Investor
    BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell technologies and therapeutics, announced that it has signed a $250,000 common stock purchase agreement with a single accredited investor. [BrainStorm Cell Therapeutics Inc. Press Release]

    POLICY NEWS

    National Institutes of Health (United States)

    Food and Drug Administration (United States)

    Center for Biologics Evaluation and Research (United States)

    European Medicines Agency (European Union)

    Medicines and Healthcare Products Regulatory Agency (United Kingdom)

    Therapeutic Goods Administration (Australia)

    EVENTS

    NEW 6th Annual Wisconsin Stem Cell Symposium: Reprogramming and Controlling Stem Cell Phenotype 
    April 27, 2011 
    Madison, United States

    Visit our events page to see a complete list of events in the mesenchymal cell community.

    JOB OPPORTUNITIES

    Lab Technologist – Cell Separation (STEMCELL Technologies)

    Lab Technologist – Human Embryonic and Induced Pluripotent Stem Cells (STEMCELL Technologies)

    Lab Technologist – Tissue Culture (STEMCELL Technologies)

    Assistant Professor (University of Pittsburgh School of Medicine, Center for Cellular and Molecular Engineering)

    PhD Fellowship: Transcriptional Networks Regulating Mesenchymal Stem Cell Differentiation (University of Southern Denmark, Odense)

    Field Applications Specialist – Cell Therapy (Pall Corporation) 


    Recruit Top Talent
    Reach more than 11,000 potential candidates by posting your organization’s career opportunities with the Connexon Creative Job Board at no cost.

    Visit here to post your career opportunities.

    Have we missed an important article or publication in Mesenchymal Cell News? Click here to submit!

    Comments or Suggestions? Email info@connexoncreative.com with your feedback.

    Learn more about Mesenchymal Cell News: Archives | Events | Contact Us